Merck & Co buys Clostridium difficile combination rights for $225 million
This article was originally published in Scrip
Executive Summary
Merck & Co has acquired the worldwide rights to a biologic treatment for Clostridium difficile infection in a $225 million deal with Medarex and Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts medical school.